Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00569751 · ClinicalTrials.gov registry record · Phase 4
TAXUS ARRIVE 2: A Multi-Center Safety Surveillance Program
A Phase 4 study, sponsored by Boston Scientific Corporation.
- Completed
- Registry status
- Phase 4
- Development phase
- 5,016
- Enrollment target
NCT00569751: Completed Phase 4 study, sponsored by Boston Scientific Corporation.
NCT00569751 is a Phase 4 study that has completed, run by Boston Scientific Corporation. The registered enrollment target is 5,016 participants, above the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (868% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00569751, a Phase 4 study, has completed, sponsored by Boston Scientific Corporation.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 5,016 participants
- Enrollment target
Study Summary
The TAXUS ARRIVE 2 study is a multi-center safety and surveillance study designed to to compile safety surveillance and clinical outcomes data for the TAXUS™ Express2™ Paclitaxel-Eluting Coronary Stent System in routine clinical practice and to identify low frequency TAXUS related clinical events.
Interventions
- DEVICE TAXUS™ Express2™ Paclitaxel-Eluting Coronary Stent System
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5,016 participants |
| Start Date | 2004-10 |
| Est. Completion | 2008-07 |
| Phase | Phase 4 |
What the finished NCT00569751 record still lists
NCT00569751 is an interventional study that assigns participants to a tested intervention. Its 5,016 participants enrollment target places it among the larger protocols in the corpus, above the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (868% higher).
The record links to 0 conditions, and to 1 intervention - of which TAXUS™ Express2™ Paclitaxel-Eluting Coronary Stent System is the first listed.
NCT00569751 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00569751 about?
NCT00569751 is a clinical study titled "TAXUS ARRIVE 2: A Multi-Center Safety Surveillance Program". The TAXUS ARRIVE 2 study is a multi-center safety and surveillance study designed to to compile safety surveillance and clinical outcomes data for the TAXUS™ Express2™ Paclitaxel-Eluting Coronary Stent System in routine clinical practice and to identify low frequency TAXUS related clinical events.
What is the current status of trial NCT00569751?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 5,016 participants. The study started on 2004-10. Estimated completion is 2008-07.
What interventions are being tested in trial NCT00569751?
The interventions under investigation include: TAXUS™ Express2™ Paclitaxel-Eluting Coronary Stent System (DEVICE).
Who is sponsoring clinical trial NCT00569751?
This trial is sponsored by Boston Scientific Corporation, which has 280 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00569751's enrollment target sits among peer trials
5,016 16th of 2000 higher than 1,985 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04743362 · 5,010 participants
A Study of Noninvasive Methods to Evaluate Skin and Mucosal Conditions
- NCT00060541 · 5,000 participants
Evaluation and Treatment of Neurosurgical Disorders
- NCT00575081 · 5,000 participants
Physiological Brain Atlas Development
- NCT00736749 · 5,000 participants
Long-Term Follow-Up of Patients Who Have Participated in Children's Oncology Group Studies
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia